Search
Phosphonotyrosine
go.drugbank.com/drugs/DB01962ExperimentalAn amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
Cry5B
go.drugbank.com/drugs/DB17783ExperimentalCry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.
2X-121
go.drugbank.com/drugs/DB16063Investigational2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the
AZD-8186
go.drugbank.com/drugs/DB15029Investigationalinvestigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by
ADU-S100
go.drugbank.com/drugs/DB14722InvestigationalADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system.
Berdazimer
go.drugbank.com/drugs/DB18712Approved[A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this
Cetyl ethylhexanoate
go.drugbank.com/drugs/DB11349InvestigationalCetyl ethylhexanoate is an ester of cetyl alcohol and 2-ethylhexanoic acid. It is present in cosmetic products as a skin conditioning agent and emollient.
Macadamia seed oil glycereth-8 esters
go.drugbank.com/drugs/DB14318InvestigationalIt is not an approved drug.
Selodenoson
go.drugbank.com/drugs/DB16325InvestigationalSelodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1-adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation).